Atara Biotherapeutics Inc. (NASDAQ:ATRA) shot up 3.5% during trading on Wednesday . The company traded as high as $23.67 and last traded at $23.64, with a volume of 67,006 shares. The stock had previously closed at $22.83.

A number of brokerages have commented on ATRA. Jefferies Group restated a “buy” rating and set a $25.00 price objective (up from $22.00) on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. JMP Securities restated a “buy” rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Zacks Investment Research lowered Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd. Finally, Canaccord Genuity restated a “buy” rating on shares of Atara Biotherapeutics in a research report on Tuesday, June 7th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $27.71.

The stock’s 50 day moving average is $21.73 and its 200 day moving average is $18.94. The stock’s market capitalization is $687.27 million.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Thursday, May 5th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by $0.03. During the same period last year, the business earned ($0.42) EPS. Equities research analysts anticipate that Atara Biotherapeutics Inc. will post ($2.64) earnings per share for the current year.

In related news, COO Gad Soffer sold 5,427 shares of the business’s stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $15.91, for a total value of $86,343.57. Following the sale, the chief operating officer now directly owns 138,125 shares in the company, valued at approximately $2,197,568.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Isaac E. Ciechanover sold 12,000 shares of the business’s stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $20.53, for a total transaction of $246,360.00. Following the completion of the sale, the chief executive officer now owns 223,228 shares in the company, valued at $4,582,870.84. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Atara Biotherapeutics stock. Jennison Associates raised its stake in Atara Biotherapeutics Inc. (NASDAQ:ATRA) by 40.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 844,180 shares of the company’s stock after buying an additional 244,695 shares during the period. Jennison Associates owned about 2.95% of Atara Biotherapeutics worth $26,541,000 as of its most recent filing with the SEC.

Atara Biotherapeutics, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company’s lead product candidate, PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction, thereby blocking the negative regulation of skeletal muscle growth.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.